Maximizing the Benefit of Renin-Angiotensin Blocking Drugs in Diabetic Renal Disease.
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00240019|
Recruitment Status : Completed
First Posted : October 17, 2005
Last Update Posted : October 17, 2006
|Condition or disease||Intervention/treatment||Phase|
|Diabetic Nephropathy||Drug: Addition of furosemide 20 mg oral bid to baseline regimen||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Maximizing the Benefit of RAS Blockade in Diabetic Nephropathy|
|Study Start Date :||December 2003|
|Study Completion Date :||April 2006|
- The amount of protein in the urine after 8 weeks of treatment.
- The estimated glomerular filtration rate after 8 weeks of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00240019
|United States, California|
|Kaiser Permanente of Northern California, Santa Clara and San Jose|
|Santa Clara, California, United States, 95051|
|Stanford University Medical Center|
|Stanford, California, United States, 94305|
|Principal Investigator:||Timothy W Meyer, MD||Stanford University|